Searchable abstracts of presentations at key conferences on calcified tissues

ba0005p35 | Bone biomechanics and quality | ECTS2016

Bone material properties as measured by Reference Point Indentation are low in subjects with acromegaly

Malgo Frank , Hamdy Neveen A T , Pereira Alberto M , Biermasz Nienke R , Appelman-Dijkstra Natasha M

Introduction: Acromegaly is a rare disease caused by excess growth hormone (GH) production by an adenoma of the anterior pituitary gland. The skeletal complications of GH and IGF-1 excess include increased bone turnover, increased cortical bone mass and deteriorated microarchitecture of trabecular bone, associated with a high risk of vertebral fractures in the presence of a relatively normal Bone Mineral Density (BMD). There are no data on bone material properties in patients ...

ba0007p109 | (1) | ICCBH2019

Fracture prevalence in children 0–19 years-old in Mexico: A 10-year cross-sectional analysis

Clark Patricia , Barbato Annarella , Guagnelli Miguel Angel , Rascon Jose Alberto , Denova Edgar , Borja Victor Hugo

Fracture prevalence in children appears to change in recent years due to variations in physical activity and enforcement of laws that protect children within motor vehicles. However, in Mexico such variation has not been explored so far.Objective: To analyze fracture prevalence in the paediatric population of Mexico to detect patterns of change in time, between genres and among different diagnoses.Methods: We analyzed data from the...

ba0001pp446 | Osteoporosis: treatment | ECTS2013

Effects of odanacatib on BMD and safety in the treatment of osteoporosis in postmenopausal women previously treated with alendronate– a randomized placebo-controlled trial

Chapurlat Roland , De Villiers Tobias , Bonnick Sydney , Odio Alberto , Palacios Santiago , Scott Boyd , De Tilleghem Celine Le Bailly , DaSilva Carolyn , Leung Albert , Gurner Deborah

Odanacatib (ODN) is an orally-active cathepsin K inhibitor being developed for the treatment of postmenopausal osteoporosis. This study evaluated the effects of ODN 50mg once weekly on BMD, bone turnover markers and safety in patients previously treated with alendronate (ALN).This was a randomized, double-blind, placebo-controlled, 24-month study. The primary endpoint was % change from baseline at month 24 of femoral neck (FN) BMD. Postmenopausal women (...

ba0002p140 | (1) | ICCBH2013

Defects of SERPINF1 cause progressively deforming recessive osteogenesis imperfecta with normal collagen I

Venturi Giacomo , Gandini Alberto , Monti Elena , Corradi Massimiliano , Vincenzi Monica , Piona Claudia , Maines Evelina , Morandi Grazia , Pepaj Orsiol , Antoniazzi Franco

Background: Osteogenesis Imperfecta is commonly due to dominant mutations in type I collagen genes, COL1A1 and COL1A2. Recessive forms, which are rarer, are caused instead by mutations in various genes coding for proteins involved in collagen post-translational modifications, folding and secretion. A novel disease locus, SERPINF1, coding for pigment-epithelium-derived-factor (PEDF), a likely key factor in bone deposition and remodelling, has been fou...

ba0002p141 | (1) | ICCBH2013

Novel splicing mutation in FKBP10 gene in a patient with moderate/severe form of osteogenesis imperfecta

Venturi Giacomo , Gandini Alberto , Monti Elena , Corradi Massimiliano , Vincenzi Monica , Piona Claudia , Morandi Grazia , Pepaj Orsiol , Antoniazzi Franco

Background: Osteogenesis imperfecta (OI) is a group of hereditary disorders characterized by bone fragility and osteopaenia, with a broad spectrum of clinical severity. The majority of cases are dominantly inherited and due to mutations in type I collagen genes, whereas recessive forms are less frequent and attributable to mutations in different genes involved in collagen I post translational modifications and folding (prolyl-3-hydroxylase complex, SERPINH1, FKBP1...

ba0002p145 | (1) | ICCBH2013

The recurrent IFITM5 c.−14C>T transition which causes osteogenesis imperfecta type V occurs at a highly methylated CpG dinucleotide: a novel mutational hot-spot?

Monti Elena , Mottes Margherita , Venturi Giacomo , Corradi Massimiliano , Gandini Alberto , Maines Evelina , Morandi Grazia , Piona Claudia , Antoniazzi Franco

Background: Osteogenesis imperfecta (OI) is a heterogeneous group of disorders characterized by bone fragility. The current classification comprises five forms (OI types I–V) with autosomal dominant inheritance and seven rarer forms (OI types VI–XII) with recessive inheritance. OI type V (MIM 610967) has distinguishing radiological features, such as propensity to hyperplastic callus formation, calcification of the forearm interosseous membrane, radial-head dislocatio...

ba0001pp104 | Calciotropic and phosphotropic hormones and mineral metabolism | ECTS2013

Neonatal neuroendocrine alterations impair tooth eruption, enamel mineralization, and leptin and corticosterone secretion in adulthood

de Mello Wagner Garcez , de Morais Samuel Rodrigues Lourenco , Delbem Alberto Carlos Botazzo , Dornelles Rita Cassia Menegati , Antunes-Rodrigues Jose , de Castro Joao Cesar Bedran

There is a growing body of evidence indicating the important role of the neonatal steroid milieu in programming sexually dimorphic pattern in various physiological systems. We tested the hypothesis that abnormal exposure to steroid hormones within a critical developmental period elicits permanent changes on tooth eruption, enamel mineralization, and leptin and corticosterone concentrations in adulthood. Newborn Wistar rats were divided into four groups, two male groups and two...

ba0001pp482 | Other diseases of bone and mineral metabolism | ECTS2013

Zoledronate efficacy and safety in active Paget's disease: long-term follow-up and retreatment in clinical practice

Vieira-Sousa Elsa , Rodrigues Ana , Caetano-Lopes Joana , Capela Susana , Ramos Filipa , Figueira Ricardo , Joaquim Polido-Pereira1 , Ponte Cristina , Raquel Campanilho-Marques1 , Barros Rita , Romeu Jose Carlos , da Silva Jose Alberto Pereira

Background: Zoledronate, a third generation bisphosphonate, has showed high efficacy in the inhibition of bone resorption. The objective of this observational study was to assess short and long-term efficacy and safety of zoledronate in the treatment of active Paget’s disease (PD).Methods: Patients with active PD treated with zoledronate 5 mg were consecutively recruited. Clinical and laboratory parameters were determined before, at 3 and every 6 mo...

ba0001pp191 | Cell biology: osteoblasts and bone formation | ECTS2013

Nuclear translocation of oxytocin receptor mediates increased gene expression in osteoblasts

Di Benedetto Adriana , Cuscito Concetta , Colaianni Graziana , Tamma Roberto , Nico Beatrice , Calvano Damiana , Zambonin Carlo , Corcelli Michelangelo , Zallone Alberta

The neuro-hypophiseal hormone oxytocin (OT) is a novel anabolic regulator of bone mass (Tamma et al. PNAS, 2009), upregulating expression of critical osteoblast transcription factors. These effects are mediated by oxytocin receptor, a GPCR expressed by osteoblasts. Recently an increasing number of reports indicates that GPCRs could be targeted to the nuclear membrane; prostaglandin receptors, endothelin receptors and β-adrenergic receptors among others (...